MSI1 and cancer: This review focuses on RBPs, particularly HuR, NONO, IGF2BP2 and 3, Musashi1 and 2, Lin28, RBM, Pumilio, YTHDF1, and AUF1, which are most extensively studied in association with cancer drug resistance.